Reply
Ophthalmology
.
2019 Dec;126(12):e96-e97.
doi: 10.1016/j.ophtha.2019.08.016.
Authors
Pravin U Dugel
1
,
Adrian Koh
2
,
Yuichiro Ogura
3
,
Glenn J Jaffe
4
,
Ursula Schmidt-Erfurth
5
,
David M Brown
6
,
Andre V Gomes
7
,
James Warburton
8
,
Andreas Weichselberger
8
,
Frank G Holz
9
;
HAWK and HARRIER Study Investigators
Affiliations
1
Retinal Consultants of Arizona, Phoenix, Arizona; University of Southern California, Los Angeles, California. Electronic address: pdugel@gmail.com.
2
Eye & Retina Surgeons, Singapore.
3
Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
4
Duke Eye Center, Durham, North Carolina.
5
Medical University of Vienna, Vienna, Austria.
6
Retina Consultants of Houston, Houston, Texas.
7
University of Sao Paulo, Sao Paulo, Brazil.
8
Novartis Pharma AG, Basel, Switzerland.
9
University of Bonn, Bonn, Germany.
PMID:
31759510
DOI:
10.1016/j.ophtha.2019.08.016
No abstract available
Publication types
Letter
Comment
MeSH terms
Animals
Antibodies, Monoclonal, Humanized
Double-Blind Method
Hawks*
Macular Degeneration*
Substances
Antibodies, Monoclonal, Humanized
brolucizumab